Glycopyranosyl lipid adjuvant (Immune Design)

N/A

Report date: 2026/04/10 20:01:49
NME

Base Information

Drug NameGlycopyranosyl lipid adjuvant (Immune Design)
Drug Alias NameGlucopyranosyl lipid adjuvantGlycopyranosyl lipid AG-100GLAG100 +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionToll like receptor 4 agonists
TargetsToll like receptor 4
Therapy Area/IndicationsSkin MelanomaSarcomaHIV Infections +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesFranceBrazil +[4] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesImmune Design
China Registration ClassN/A

Develop Information

Active CompaniesNational Institute Of Allergy And Infectious Diseases (Niaid)George Washington University (The)
Inactive CompaniesChildren'S National Research InstituteInstitut National De La Santé Et De La Recherche Médicale, France U979Access to Advanced Health Institute +[6] 
Active IndicationsHIV InfectionsHookworm InfectionsTuberculosis, Pulmonary
Inactive IndicationsSkin MelanomaSarcomaMalaria, Falciparum +[5] 

Other Information

ATC CodeN/A
Related LinksN/A